enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...

3. Molecule ‘shows promise’ as effective first line of prostate ...

   www.aol.com/molecule-shows-promise-effective...

   Prostate cancer is the most common cancer in men in the UK, with more than 52,000 cases diagnosed every year on average. Current treatments include radiation, chemotherapy, hormone deprivation ...

4. Delaying localised prostate cancer treatment ‘does not ...

   www.aol.com/delaying-localised-prostate-cancer...

   Delaying treatment for localised prostate cancer does not increase the risk of death, new research suggests. According to a new study, active monitoring of the disease has the same high survival ...

5. What You Need to Know About Prostate Cancer Treatments - AOL

   www.aol.com/lifestyle/know-prostate-cancer...

   Doctors recommend different treatments depending on the cancer case. From active surveillance to surgery and targeted therapies, here's what the options are.

6. Sipuleucel-T - Wikipedia

   en.wikipedia.org/wiki/Sipuleucel-T

   Shortly afterward, sipuleucel-T was added to the compendium of cancer treatments published by the National Comprehensive Cancer Network (NCCN) as a "category 1" (highest recommendation) treatment for HRPC. The NCCN Compendium is used by Medicare and major health care insurance providers to decide whether a treatment should be reimbursed. [14] [15]

7. Prostvac - Wikipedia

   en.wikipedia.org/wiki/Prostvac

   PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]